Crinetics Pharmaceuticals Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crinetics Pharmaceuticals Inc (CRNX).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

3S.Buy

9Buy

7Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$82Upside to Avg. PT-3.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	Cantor Fitzgerald	Josh Schimmer	Suspends	Neutral	—
Jul 28, 2026	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$55→$85
Jul 8, 2026	TD Cowen	Tyler Van Buren	Downgrade	Buy→Hold	—
Jul 8, 2026	Evercore ISI Group	Gavin Clark-Gartner	Downgrade	Outperform→In-Line	$88→$85
Jul 7, 2026	Jones Trading	—	Downgrade	Buy→Hold	$85
Jul 7, 2026	Jefferies	Dennis Ding	Downgrade	Buy→Hold	$55→$85
Jul 7, 2026	Oppenheimer	Leland Gershell	Downgrade	Outperform→Perform	—
Jul 7, 2026	Cantor Fitzgerald	Josh Schimmer	Downgrade	Overweight→Neutral	—
Jul 7, 2026	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$81→$85
Jul 7, 2026	Baird	Brian Skorney	PT Raise	Outperform	$62→$85
Jul 2, 2026	UBS	Ashwani Verma	Initiate	Buy	$55
Jun 15, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$81
Jun 11, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$95
May 15, 2026	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$89→$88
May 11, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$87→$84
May 8, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$97→$95
Apr 28, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$96→$97
Mar 2, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$105→$96
Jan 12, 2026	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$67
Jan 8, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$108→$105